Clifford Swan Investment Counsel LLC decreased its stake in Teva Pharmaceutical Industries (NYSE:TEVA) by 12.5% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 136,904 shares of the company’s stock after selling 19,610 shares during the period. Clifford Swan Investment Counsel LLC’s holdings in Teva Pharmaceutical Industries were worth $2,340,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Teachers Advisors LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 66.5% in the 4th quarter. Teachers Advisors LLC now owns 3,221,405 shares of the company’s stock valued at $61,046,000 after buying an additional 1,286,637 shares in the last quarter. Millennium Management LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 56.6% in the 4th quarter. Millennium Management LLC now owns 2,965,936 shares of the company’s stock valued at $56,204,000 after buying an additional 1,071,583 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec boosted its holdings in shares of Teva Pharmaceutical Industries by 1,498.9% in the 4th quarter. Caisse DE Depot ET Placement DU Quebec now owns 328,228 shares of the company’s stock valued at $6,220,000 after buying an additional 307,700 shares in the last quarter. Meitav Dash Investments Ltd. acquired a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $5,017,000. Finally, Synovus Financial Corp boosted its holdings in shares of Teva Pharmaceutical Industries by 27.7% in the 4th quarter. Synovus Financial Corp now owns 27,817 shares of the company’s stock valued at $530,000 after buying an additional 6,029 shares in the last quarter. Institutional investors and hedge funds own 58.18% of the company’s stock.

TEVA stock opened at $20.88 on Thursday. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 1.80. The firm has a market capitalization of $20.72 billion, a PE ratio of 5.31, a PEG ratio of 1.67 and a beta of 0.67. Teva Pharmaceutical Industries has a one year low of $20.87 and a one year high of $21.36.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Thursday, May 3rd. The company reported $0.91 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.63 by $0.28. The business had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.80 billion. Teva Pharmaceutical Industries had a negative net margin of 72.36% and a positive return on equity of 18.59%. The business’s revenue was down 10.0% compared to the same quarter last year. During the same quarter last year, the firm posted $1.06 EPS. research analysts expect that Teva Pharmaceutical Industries will post 2.44 EPS for the current year.

TEVA has been the subject of a number of recent research reports. ValuEngine cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 2nd. Vetr cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating and set a $21.73 price target for the company. in a research note on Monday, March 12th. Bank of America decreased their price target on shares of Teva Pharmaceutical Industries from $17.00 to $16.00 and set an “underperform” rating for the company in a research note on Friday, February 9th. Jefferies Group initiated coverage on shares of Teva Pharmaceutical Industries in a research note on Tuesday, March 20th. They set a “hold” rating and a $19.00 price target for the company. Finally, Zacks Investment Research upgraded shares of Teva Pharmaceutical Industries from a “sell” rating to a “hold” rating in a research note on Wednesday, May 9th. Ten research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $19.82.

In related news, Director Roberto Mignone purchased 750,000 shares of the business’s stock in a transaction dated Thursday, May 10th. The stock was acquired at an average price of $19.24 per share, for a total transaction of $14,430,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders sold a total of 5,684 shares of company stock valued at $105,411 in the last quarter. Insiders own 0.43% of the company’s stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.